A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group

Can J Neurol Sci. 1987 Aug;14(3):273-8. doi: 10.1017/s0317167100026603.


One hundred and fifteen patients with definite multiple sclerosis (M.S.) and chronic persistent fatigue were studied. This ten-week cross-over study consisted of a 2-week baseline period and two 3-week treatment periods separated by a 2-week washout. Patients received either amantadine 100 mg bid or matching placebo capsules. Fatigue, the effect of fatigue on an individually pre-selected activity and its effect on activities of daily living, were evaluated. Amantadine produced a small but statistically significant decrease in fatigue. An important placebo effect was noted. Mean fatigue during the washout period was lower than during the placebo run-in period, independently of which treatment had been given first. Side effects were numerous both on amantadine and on placebo. Only insomnia was significantly more common with amantadine.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Activities of Daily Living
  • Adult
  • Amantadine / adverse effects
  • Amantadine / therapeutic use*
  • Clinical Trials as Topic
  • Depression / drug therapy
  • Depression / etiology
  • Double-Blind Method
  • Fatigue / drug therapy*
  • Fatigue / etiology
  • Female
  • Humans
  • Male
  • Multiple Sclerosis / complications*
  • Random Allocation


  • Amantadine